{"prompt": "['Novartis', 'Confidential', 'Page 24', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Review Visit 1 or Visit 101 or the one additional attempt reversibility result from overread', 'by the spirometry vendor central reader prior to randomization.', '9. An ACQ score > 1.5 at Visit 199.', '4.2', 'Exclusion criteria', 'Patients fulfilling any of the following criteria are not eligible for inclusion in this study. No', 'additional exclusions may be applied by the investigator, in order to ensure that the study', 'population will be representative of all eligible patients.', '1.', 'Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days,', 'whichever is longer.', '2.', 'History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar', 'chemical classes to QAW039.', '3. History of lactose or milk sensitivity.', '4. Patients with a history or current diagnosis of ECG abnormalities indicating significant', 'risk of safety for patients participating in the study such as:', 'Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular', 'tachycardia, and clinically significant second or third degree atrioventricular (AV)', 'block without a pacemaker.', 'History of familial long QT syndrome or known family history of Torsades de Pointes.', '5. Patients with a resting QTcF (Fridericia) >450 msec (male) or >460 msec (female) at Visit', '1.', '6. Use of agents known to prolong the QT interval unless it can be permanently discontinued', 'for the duration of the study.', '7. Patients with a history of malignancy of any organ system (other than localized basal cell', 'carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5', 'years, regardless of whether there is evidence of local recurrence or metastases.', '8. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female', 'after conception and until the termination of gestation, confirmed by a positive human', 'chorionic gonadotropin (hCG) laboratory test.', '9. Women of child-bearing potential, defined as all women physiologically capable of', 'becoming pregnant, unless they are using basic methods of contraception during dosing of', 'study drug. Basic contraception methods include:', 'Total abstinence (when this is in line with the preferred and usual lifestyle of the', 'subject) if allowed as an effective method of contraception by local regulations.', 'Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods)', 'and withdrawal are not acceptable methods of contraception', 'Female sterilization (have had surgical bilateral oophorectomy with or without', 'hysterectomy) or tubal ligation at least six weeks before taking study treatment. In', 'case of oophorectomy alone, only when the reproductive status of the woman has', 'been confirmed by follow up hormone level assessment', 'Male sterilization (at least 6 months prior to screening). For female patients on the', 'study, the vasectomized male partner must be the sole partner for that subject']['Novartis', 'Confidential', 'Page 25', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Barrier methods of contraception: Condom or Occlusive cap (diaphragm or', 'cervical/vault caps) if allowed as an effective method of contraception by local', 'regulations. For United Kingdom: with spermicidal foam/gel/film/cream/vaginal', 'suppository', 'Use of oral, injected* or implanted* hormonal methods of contraception or other', 'forms of hormonal contraception that have comparable efficacy (failure rate <1%), for', 'example hormone vaginal ring or transdermal hormone contraception', 'Placement of an intrauterine device (IUD) or intrauterine system (IUS)', '*Not approved in Japan', 'In case of use of oral contraception women must have been stable on the same pill for a', 'minimum of 3 months before taking study drug.', 'In case local regulations deviate from the contraception methods listed above, local', 'regulations apply and will be described in the informed consent form (ICF).', 'Women are considered post-menopausal and not of child bearing potential if they have', 'had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical pro file', '(e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral', 'oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In', 'the case of oophorectomy alone, only when the reproductive status of the woman has', 'been confirmed by follow up hormone level assessment is she considered not of child', 'bearing potential.', '10. Patients who have smoked or inhaled any substance other than asthma medications within', 'the 6 month period prior to Visit 1, or who have a cigarette smoking history of greater', 'than 10 pack years (Note: 10 pack years = 1 pack /day X 10 yrs., or 1/2 pack/day X 20 yrs.).', '11. Patients who have had an asthma exacerbation requiring systemic corticosteroids,', 'hospitalization, or emergency room visit within 6 weeks prior to Visit 1.', '12. Patients who have an asthma exacerbation requiring systemic corticosteroids,', 'hospitalization or emergency room visit during the screening or placebo run-in periods.', 'Patients who experience an asthma exacerbation during screening may be re-screened 4', 'weeks after complete recovery from the exacerbation.', '13. Patients who have had a respiratory tract infection or asthma worsening within 4 weeks of', 'Visit 1. Patients who experience a respiratory tract infection or asthma worsening during', 'screening may be re-screened after 4 weeks after recovery.', '14. Patients with any chronic condition of the respiratory tract which in the opinion of the', 'investigator may interfere with study evaluation or optimal participation in the study.', '15. Patients with a history of chronic lung disease other than asthma, including (but not', 'limited to) chronic obstructive pulmonary disease (as defined by Global Initiative For', 'Chronic Obstructive Lung Disease (GOLD) standards), bronchiectasis, (non-clinically', 'significant bronchiectasis may be allowed provided recent (within 3 months prior to Visit', '101) computed tomography (CT) scan proof is available), sarcoidosis interstitial lung', 'disease, cystic fibrosis, and tuberculosis.', '16. Patients with a history of conditions other than asthma or allergic rhinitis that could result', 'in elevated eosinophils (e.g., hypereosinophilic syndromes, Churg-Strauss Syndrome,']\n\n###\n\n", "completion": "END"}